Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases

Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases

Aim. To evaluate the role of polymorphisms in adrenoceptor beta 1 (ADRB1) (Arg389Gly, rs1801253) and angiotensin-converting enzyme (ACE) (I/D, rs4343) genes in assessing the effectiveness of β-blocker (carvedilol) and ACE inhibitor (enalapril) therapy in women with anthracycline-induced cardiotoxici...

Full description

Saved in:
Bibliographic Details
Main Authors: E. V. Grakova, K. V. Kopeva, S. N. Shilov, E. N. Berezikova, A. A. Popova, M. N. Neupokoeva, E. T. Ratushnyak, V. V. Kalyuzhin, A. T. Teplyakov
Format: Article
Language:English
Published: Siberian State Medical University (Tomsk) 2023-01-01
Series:Бюллетень сибирской медицины
Subjects:
anthracycline-induced cardiotoxicity
heart failure
gene polymorphisms
β-blocker
angiotensin-converting enzyme inhibitor
Online Access:https://bulletin.ssmu.ru/jour/article/view/5020
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bulletin.ssmu.ru/jour/article/view/5020

Similar Items